ATE392421T1 - Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung - Google Patents
Von pyrazol abgeleitete kinaseinhibitoren und deren verwendungInfo
- Publication number
- ATE392421T1 ATE392421T1 AT02756943T AT02756943T ATE392421T1 AT E392421 T1 ATE392421 T1 AT E392421T1 AT 02756943 T AT02756943 T AT 02756943T AT 02756943 T AT02756943 T AT 02756943T AT E392421 T1 ATE392421 T1 AT E392421T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- kinase inhibitors
- pyrazole
- derived kinase
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30986501P | 2001-08-03 | 2001-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE392421T1 true ATE392421T1 (de) | 2008-05-15 |
Family
ID=23200008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02756943T ATE392421T1 (de) | 2001-08-03 | 2002-08-02 | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
Country Status (9)
Country | Link |
---|---|
US (2) | US6750239B2 (de) |
EP (1) | EP1423382B1 (de) |
JP (1) | JP4357295B2 (de) |
AT (1) | ATE392421T1 (de) |
AU (1) | AU2002321910A1 (de) |
CA (1) | CA2456192A1 (de) |
DE (1) | DE60226154T2 (de) |
MX (1) | MXPA04001087A (de) |
WO (1) | WO2003011855A2 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1423382B1 (de) * | 2001-08-03 | 2008-04-16 | Vertex Pharmaceuticals Incorporated | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
UA79804C2 (en) * | 2002-07-03 | 2007-07-25 | Janssen Pharmaceutica Nv | Cck-1 receptor modulators |
US7094791B2 (en) * | 2003-07-31 | 2006-08-22 | Avalon Pharmaceuticals, Inc. | Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof |
DE602004012578T2 (de) | 2003-08-15 | 2008-12-11 | Vertex Pharmaceuticals Inc., Cambridge | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen |
NZ547696A (en) | 2003-12-23 | 2009-12-24 | Astex Therapeutics Ltd | Pyrazole derivatives as protein kinase modulators |
WO2005102346A2 (en) * | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating fibrosis |
TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
PT1853588E (pt) * | 2005-02-16 | 2008-08-25 | Astrazeneca Ab | Compostos químicos |
KR20080015409A (ko) * | 2005-05-16 | 2008-02-19 | 아스트라제네카 아베 | 티로신 키나제 억제제로서 유용한 피라졸릴아미노피리미딘 유도체 |
WO2006136823A1 (en) * | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
EP1902032A1 (de) * | 2005-06-22 | 2008-03-26 | Astex Therapeutics Limited | Pharmazeutische verbindungen |
EP1933832A2 (de) | 2005-06-23 | 2008-06-25 | Astex Therapeutics Limited | Pharmazeutische kombinationen mit pyrazol-derivaten als proteinkinase-modulatoren |
EP1945631B8 (de) * | 2005-10-28 | 2013-01-02 | AstraZeneca AB | 4-(3-aminopyrazol)pyrimidinderivate zur verwendung als tyrosinkinaseinhibitoren bei der behandlung von krebs |
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
CN101389324A (zh) * | 2005-12-23 | 2009-03-18 | 史密丝克莱恩比彻姆公司 | Aurora激酶的氮杂吲哚抑制剂 |
CA2642762A1 (en) | 2006-02-16 | 2007-08-30 | Schering Corporation | Pyrrolidine derivatives as erk inhibitors |
US8173365B2 (en) | 2006-03-24 | 2012-05-08 | The University Of Tokyo | Method for inhibiting signal transduction, signal transduction inhibitor to be used therein and use thereof |
UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
ES2543325T3 (es) * | 2007-02-07 | 2015-08-18 | Glaxosmithkline Llc | Inhibidores de la actividad de Akt |
GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
CN101679429A (zh) * | 2007-04-18 | 2010-03-24 | 阿斯利康(瑞典)有限公司 | 5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途 |
ES2369596T3 (es) * | 2007-05-04 | 2011-12-02 | Astrazeneca Ab | Derivados de amino-tiazolil-pirimidina y su uso para el tratamiento del cáncer. |
UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
JP5276676B2 (ja) | 2008-02-21 | 2013-08-28 | メルク・シャープ・アンド・ドーム・コーポレーション | Erk阻害剤である化合物 |
CA2727073A1 (en) * | 2008-06-11 | 2009-12-17 | Astrazeneca Ab | Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders |
US20110129455A1 (en) * | 2008-06-26 | 2011-06-02 | Hong Lin | Inhibitors of akt activity |
EP2303277A4 (de) * | 2008-06-26 | 2011-08-17 | Glaxosmithkline Llc | Hemmer der akt-aktivität |
RU2011116928A (ru) * | 2008-09-30 | 2012-11-20 | Астразенека Аб (Se) | Гетероциклические ингибиторы jак киназы |
US20110288142A1 (en) | 2009-01-30 | 2011-11-24 | Chen Pingyun Y | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
EP2642856B1 (de) | 2010-11-24 | 2017-07-19 | The Ohio State University Research Foundation | Integrin-gekoppelte kinasehemmer |
US9303024B2 (en) | 2011-10-11 | 2016-04-05 | Dana-Farber Cancer Institute, Inc. | Pyrazol-3-ones that activate pro-apoptotic BAX |
WO2014138661A1 (en) | 2013-03-08 | 2014-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837719A (en) * | 1995-08-10 | 1998-11-17 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
US6087496A (en) * | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
AU7726898A (en) * | 1997-05-22 | 1998-12-11 | G.D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
BR0104424A (pt) | 2000-02-05 | 2002-01-08 | Vertex Pharma | Composições de pirazol úteis como inibidores de erk |
EP1423382B1 (de) * | 2001-08-03 | 2008-04-16 | Vertex Pharmaceuticals Incorporated | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
-
2002
- 2002-08-02 EP EP02756943A patent/EP1423382B1/de not_active Expired - Lifetime
- 2002-08-02 WO PCT/US2002/024725 patent/WO2003011855A2/en active Application Filing
- 2002-08-02 AT AT02756943T patent/ATE392421T1/de not_active IP Right Cessation
- 2002-08-02 CA CA002456192A patent/CA2456192A1/en not_active Abandoned
- 2002-08-02 US US10/212,294 patent/US6750239B2/en not_active Expired - Fee Related
- 2002-08-02 MX MXPA04001087A patent/MXPA04001087A/es unknown
- 2002-08-02 AU AU2002321910A patent/AU2002321910A1/en not_active Abandoned
- 2002-08-02 DE DE60226154T patent/DE60226154T2/de not_active Expired - Lifetime
- 2002-08-02 JP JP2003517047A patent/JP4357295B2/ja not_active Expired - Fee Related
-
2004
- 2004-05-03 US US10/837,848 patent/US7183307B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2003011855A3 (en) | 2003-09-25 |
JP4357295B2 (ja) | 2009-11-04 |
CA2456192A1 (en) | 2003-02-13 |
DE60226154T2 (de) | 2009-05-20 |
AU2002321910A1 (en) | 2003-02-17 |
WO2003011855A2 (en) | 2003-02-13 |
US6750239B2 (en) | 2004-06-15 |
DE60226154D1 (de) | 2008-05-29 |
EP1423382A2 (de) | 2004-06-02 |
US20030144337A1 (en) | 2003-07-31 |
MXPA04001087A (es) | 2004-07-08 |
US7183307B2 (en) | 2007-02-27 |
EP1423382B1 (de) | 2008-04-16 |
JP2005500353A (ja) | 2005-01-06 |
US20040209935A1 (en) | 2004-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE392421T1 (de) | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung | |
ATE491701T1 (de) | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung | |
DE60122176D1 (de) | Isoxazole und ihre verwendung als erk-inhibitoren | |
MXPA03009846A (es) | Derivados de triazol inhibidores de cinasa y usos de los mismos. | |
WO2002088090A3 (en) | Pyrazole derived kinase inhibitors | |
WO2001056993A3 (en) | Pyrazole compositions useful as inhibitors of erk | |
LT2001103A (en) | Pyrazole compositions useful as inhibitors of erk | |
AP2003002853A0 (en) | Heterocyclic inhibitors of ERK2 and uses thereof | |
ATE339418T1 (de) | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen | |
DE60315146D1 (de) | Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase | |
RS95404A (en) | Thiazolidinones and the use thereof as polo-like kinase inhibitors | |
CY1112100T1 (el) | ΝΕΑ ΕΝΩΣΗ ΤΡΙΣΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 8Η-ΠΥΡΙΔΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-7-ΟΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΑΣΘΕΝΕΙΩΝ, ΟΙ ΟΠΟΙΕΣ ΕΧΟΥΝ ΠΡΟΚΛΗΘΕΙ ΜΕ ΤΗ ΜΕΣΟΛΑΒΗΣΗ CSBP/p38 ΚΙΝΑΣΗΣ | |
PL373645A1 (en) | Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors | |
ATE495155T1 (de) | Heterocyclische inhibitoren von mek | |
ATE413388T1 (de) | Muskarin antagonisten | |
DE60205776T2 (de) | Indolinon-derivative als protein-kinasehemmer | |
DE50208918D1 (de) | 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung | |
DE60106409D1 (de) | 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen | |
NO20045025L (no) | Nye forbindelser | |
ATE287886T1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer | |
EA200301101A1 (ru) | Производные пиперазина и их применение в качестве ингибиторов pde4 | |
ATE276259T1 (de) | Dihydroporphyrinderivate und ihre verwendung | |
ATE409191T1 (de) | 1,3-diaza-dibenzoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung | |
NO20053562L (no) | Nye aminobenzofenonforbindelser | |
DE60224805D1 (de) | 1-glycinyl-4-(1-methylpiperidin-4-yl)piperazine un |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |